—
C+
C+ The full Closelook — membership. Open the C+ overview

CG Oncology, Inc. Common stock (CGON) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

44 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

102.79 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

3/8 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

248.27 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — above the −1.78 threshold the literature flags for earnings-manipulation risk. A screen, not an accusation.

Continue: the CGON chart & overview · the earnings record

FAQ · from the current data · as of 2026-09-18

Quick answers

What is CG Oncology, Inc. Common stock's Closelook quality reading?

The composite reads 44/100 across 7 modules, as of 2026-09-18: valuation 5, quality 1, growth 77, balance sheet 98, cash quality 49, capital allocation 4, momentum 77. Closelook scores are research diary readings, not ratings or investment advice.

What is CG Oncology, Inc. Common stock's Altman Z-Score?

102.79, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is CG Oncology, Inc. Common stock's Piotroski F-Score?

3 of 8, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does CG Oncology, Inc. Common stock's Beneish M-Score indicate?

248.27 — above the −1.78 threshold the literature flags for earnings-manipulation risk, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.